Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary; Department of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Turk J Gastroenterol. 2023 May;34(5):508-515. doi: 10.5152/tjg.2023.22339.
Emerging data suggest that a treat-to-target approach and early therapeutic intervention using regular objective disease assessment leads to improved outcomes. Our aim was to evaluate the value of objective disease monitoring during regular follow-up in a single tertiary inflammatory bowel disease center.
Consecutive inflammatory bowel disease patients (n = 161, Crohn's disease: 118/ulcerative colitis: 43; biological therapy: 70%) were included and followed up for 1 year between January and December 2018. Data on clinical disease activity, biomarkers, endoscopy, imaging, outpatient visits, treatment optimization, hospitalization, and surgery were collected. We compared the monitoring strategy according to the clinical activity (remission/flare/post-flare/continuous activity) every 3 months (assessment period).
In total, n = 644 assessment periods were evaluated. Biomarkers were evaluated in 82.9%-83.9% of patients in each assess ment period regardless of clinical activity. Colonoscopy was more frequently performed in active disease (flare/continuous disease activ ity: 21.1%/18.9% vs. clinical remission: 10.1% per assessment period). Magnetic resonance imaging was performed in 7.7%-16.7%/ period in Crohn's disease patients, while the use of computed tomography was low (2.4%/period) and mainly performed in active dis ease. Treatment optimization was more frequent in patients with active disease (biological start/dose optimization: 31.1%/33.8%/ period, steroid start: 13.2%/period). Patients with continuous activity (2.62), flare (2.45), and post-flare (2.05) had higher mean patient visit counts compared to remission (1.68/period).
Objective monitoring strategy was applied with routine assessment of clinical activity and biomarkers. Fast-track colo noscopic evaluations were adapted to the clinical stage of the disease while screening colonoscopies and magnetic resonance imaging were frequently used. Objective monitoring resulted in the early optimization of medical therapy and frequent specialist follow-up visits.
新出现的数据表明,采用靶向治疗和早期治疗干预,定期进行客观疾病评估可改善治疗结果。我们的目的是评估在单家三级炎症性肠病中心进行常规随访期间进行客观疾病监测的价值。
连续纳入炎症性肠病患者(n=161,克罗恩病:118/溃疡性结肠炎:43;生物治疗:70%),并于 2018 年 1 月至 12 月期间随访 1 年。收集临床疾病活动度、生物标志物、内镜、影像学、门诊就诊、治疗优化、住院和手术等数据。我们根据每 3 个月(评估期)的临床活动(缓解/发作/发作后/持续活动)比较了监测策略。
共评估了 n=644 个评估期。无论临床活动如何,在每个评估期,有 82.9%-83.9%的患者评估了生物标志物。在活动期(发作/持续活动)更频繁地进行结肠镜检查(21.1%/18.9%比临床缓解:每个评估期 10.1%)。在克罗恩病患者中,磁共振成像(MRI)的检查频率为 7.7%-16.7%/期,而计算机断层扫描(CT)的使用率较低(2.4%/期),主要用于活动期疾病。在活动期患者中更频繁地进行治疗优化(生物起始/剂量优化:31.1%/33.8%/期,起始使用类固醇:13.2%/期)。与缓解期相比,持续活动(2.62)、发作(2.45)和发作后(2.05)的患者平均就诊次数更多(每个评估期 1.68 次)。
采用靶向治疗和早期治疗干预的常规评估方法进行了客观监测策略。快速跟踪结肠镜检查适用于疾病的临床阶段,同时经常进行筛选性结肠镜检查和磁共振成像。客观监测导致早期优化医学治疗和频繁的专科随访。